---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-278805"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:27:02.529261+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio Q3 net loss $7.4M; completes Part B enrollment in SIGNAL-AA; cash runway into 2027

## Summary
- Completed enrollment in Part B of SIGNAL-AA Phase 2a trial for alopecia areata; trial size increased to 33 patients; topline data expected mid-2026.
- Cash and equivalents $49.0M as of Sep 30, 2025, expected to fund operations into 2027.
- Net loss $7.4M ($0.60 per share) vs $17.6M ($1.46 per share) in Q3 2024, driven by lower R&D spend.
- R&D expenses decreased to $3.6M from $14.3M; G&A to $4.0M from $4.5M year-over-year.
- Emerging signs of clinical activity observed; preliminary PK shows steady-state drug concentration achieved 9 weeks earlier with loading regimen.

## SEC filing metadata
- accession: 0001193125-25-278805
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312525278805/0001193125-25-278805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312525278805/qttb-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-278805
- JSON: https://secwatch.observer/filing/0001193125-25-278805.json
- Plain text: https://secwatch.observer/filing/0001193125-25-278805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.